The newly approved for trading penny stock of Sangui Biotech International Inc. (SGBI) saw it’s share price jump 150% on Tuesday with just 6 trades worth less than $8,000 to boot. Having announced that they might be on the brink of possibly treating septic shock successfully thanks to a hemoglobin based product developed by the Company to improve the oxygen supply of vital organs. Considering sepsis has a worldwide incidence of more than 20 million cases a year, with mortality due to septic shock reaching up to 50 percent even in industrialized countries, perhaps there really is something about SGBI stock that’s worth looking into.
Want to crush the Markets and make profits of $624, $2,897, even $40,656?
Click HERE To Make Sure You Get All Of Our Penny Stock Alerts!
SGBI Stock Quote
Biotechs have long been a sector where investors love to go in, park their money, and forget all about it for a couple years before coming back and finding out what’s been happening. Sangui Biotech International fits the bill appropriately for such a gesture seeing as how their news announcement from Tuesday and recent approval for their SGBI stock to be traded on the OTCQB, which was announced last week, a curious ticker for traders.
From the looks of their balance sheet, SGBI stock looks quite appetizing seeing as how the Company only had $253,313 in total liabilities as of their year ended June 30, 2014, and issued only about 10 million shares during the fiscal year for services. The Company basically funded itself issuing 8,500,500 shares of SGBI stock for cash at an average of $0.11 per share, yielding total cash proceeds of $942,915 for the year.
Sangui Biotech has been booking revenues for awhile now thanks to a JV that allows them to distribute a hemoglobin based wound spray technology in several European countries and Mexico. For the years ended June 30, 2014 and 2013, the Company booked $133,470 and $105,487, respectively, in sales which cost them virtually nothing, less than 10%, to generate.
Although net income is a far reach away from those tiny little sales figures, roughly $1.57 million and $2.26 million in losses for the 2 respective fiscal years, the news about the pre-clinical trials in Giessen that apparently demonstrate that an oxygen-carrying hemoglobin liquid in the abdomen did significantly improve the oxygen supply to the intestines could be the big break they’ve been hunting for the last nearly 20 years. It sure seems peculiar that the day the news comes out, SGBI stock climbs 150% with just 6 executed trades on the session.
Looking for the Best Penny Stocks to Buy?
Click HERE To Receive FREE Penny Stock Alerts
About SGBI Stock
Sangui Biotech International Inc. is an emerging growth biotech company that, through their German subsidiary, Sangui GmbH, is focused on the development of novel and proprietary pharmaceutical, medical and cosmetic products.
Click here to view the SEC filings for SGBI.
Click here to view the website for Sangui Biotech International Inc.
Issued and Outstanding: 144,223,056
Last 5 Trading Sessions:
The illiquidity of SGBI is likely to keep a large number of penny stock traders far enough away from it for now until volume can become consistent. With 91,062,951 shares of SGBI stock in the public float, it’s almost too hard to believe that 6 little trades could push the ticker up 150%.
[gravityform id=”6″ name=”Post” title=”false”]
(We are 100% Anti-Spam and will never rent or sell your information) Although many of our picks go up 100, 200% even 4,000%, there is always the chance a stock could move lower.
Please read and understand our rules very carefully:
1. Penny Stocks can be very dangerous, unless you understand the risk involved with them do not try to trade them. Many go up fast and can drop just as fast;
2. Do not risk too much in one company. You can lose it all very quickly;
3. Do not “marry” any one stock. Recognize if you are wrong about a stock, cut your losses and move on to the next stock; and
4. Always use stop loss orders. We recommend that you use “trailing stops” in order to protect your profits.